FDA to Merck: Mevacor OTC not approvable

Share this article:

The FDA needs to see additional data from Merck before approving an OTC version of the drugmaker's cholesterol-lowering drug Mevacor (lovastatin).

The agency requested the data along with revised labeling for the drug in a non-approvable letter sent to Merck late last week.

“We're evaluating the conditions outlined in the agency's response to determine a path forward for Mevacor OTC,” Merck VP, global OTC regulatory and scientific affairs, Edwin Hemwall said in a statement.

In December, an FDA advisory panel recommended against approval of cholesterol-lowering Mevacor without a prescription by a 10 to 2 vote.

The rejection of Mevacor OTC marks the third time a global drugmaker has failed to win FDA approval for the drug's non-prescription status.

Merck has twice failed before to convince the FDA – once in 2000 and once in 2005 – that patients could safely use Mevacor without a doctor's prescription.

Mevacor lost US patent protection in 2001, with Merck and prospective marketing partner Johnson & Johnson trying to secure OTC status in the years to follow.
 
The UK became the first nation to approve an OTC statin in 2004, allowing the sale of a 10 mg version of simvastatin, which is marketed as Zocor Heart-Pro by Merck.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.